SHANGHAI – As part of health care reforms, China has been piloting "zero markups" for drugs sold at hospitals for several years in a bid to reduce and rationalize the cost of health care.
SHANGHAI – As part of health care reforms, China has been piloting "zero markups" for drugs sold at hospitals for several years in a bid to reduce and rationalize the cost of health care. According to the State Council work plan, this year will see a significant expansion of the pilot, with half of all county-level hospitals and one city per province expected to have adopted the new drug pricing policy by the end of the year.
SHANGHAI – Yabao Pharmaceutical Co. Inc., of Beijing, has entered a partnership with Eli Lilly and Co. to co-develop Lilly's leading glucokinase activator (GKA), LY2608204, for China's diabetics.
SHANGHAI – Hong Kong-based Uni-Bio Science Group Ltd. (HKSE:690) said Uni-PTH, an anabolic agent that builds bone mass in postmenopausal women suffering from osteoporosis, has achieved its primary endpoint in a phase III trial. Uni-PTH could be considered a biosimilar of Forteo (teriparatide, Eli Lilly and Co.), but since China has no pathway to prove biosimilarity, Uni-Bio took the drug through its paces as if it were a new drug.
SHANGHAI – Hong Kong-based Uni-Bio Science Group Ltd. (HKSE:690) said Uni-PTH, an anabolic agent that builds bone mass in post-menopausal women suffering from osteoporosis, has achieved its primary endpoint in a phase III trial. Uni-PTH could be considered a biosimilar of Forteo (teriparatide, Eli Lilly and Co.). But since China has no pathway to prove biosimilarity, Uni-Bio took the drug through its paces as if it were a new drug.
SHANGHAI – Six Chinese government agencies with authority over health matters, including the CFDA and the National Health and Family Planning Commission, have issued a joint opinion on pediatric drugs in an attempt to address the problem of medicine safety for children in China.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang and Shanghai, won FDA approval for its third cancer drug, oxaliplatin, an alkylating agent used to treat colorectal cancer, as the firm's pioneering efforts as a Chinese pharma to pass the hurdles of developed markets begin to pay off.
SHANGHAI – Six Chinese government agencies with authority over health matters, including the CFDA and the National Health and Family Planning Commission, have issued a joint opinion on pediatric drugs in an attempt to address the problem of medicine safety for children in China.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang and Shanghai, won FDA approval for its third cancer drug, oxaliplatin, an alkylating agent used to treat colorectal cancer, as the firm's pioneering efforts as a Chinese pharma to pass the hurdles of developed markets begin to pay off.
SHANGHAI – Another month, another announcement for Lee's Pharmaceuticals Ltd., of Hong Kong, as it has been slowly but surely building a successful biotech business and developing and commercializing products for the China market.
